JP2013545759A - 低酸素状態に基づくエレスクロモールによる治療に適した被験体の事前選択 - Google Patents

低酸素状態に基づくエレスクロモールによる治療に適した被験体の事前選択 Download PDF

Info

Publication number
JP2013545759A
JP2013545759A JP2013540063A JP2013540063A JP2013545759A JP 2013545759 A JP2013545759 A JP 2013545759A JP 2013540063 A JP2013540063 A JP 2013540063A JP 2013540063 A JP2013540063 A JP 2013540063A JP 2013545759 A JP2013545759 A JP 2013545759A
Authority
JP
Japan
Prior art keywords
cancer
ldh
tumor
hypoxia
ldh5
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013540063A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013545759A5 (enExample
Inventor
ブラックマン，ロナルド，ケー．
ブコビック，ボジョ
Original Assignee
シンタ ファーマスーティカルズ コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シンタ ファーマスーティカルズ コーポレーション filed Critical シンタ ファーマスーティカルズ コーポレーション
Publication of JP2013545759A publication Critical patent/JP2013545759A/ja
Publication of JP2013545759A5 publication Critical patent/JP2013545759A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G01N33/5758—

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2013540063A 2010-11-18 2011-11-18 低酸素状態に基づくエレスクロモールによる治療に適した被験体の事前選択 Pending JP2013545759A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41510410P 2010-11-18 2010-11-18
US61/415,104 2010-11-18
PCT/US2011/061453 WO2012068491A1 (en) 2010-11-18 2011-11-18 Preselection of subjects for therapeutic treatment with elesclomol based on hypoxic status

Publications (2)

Publication Number Publication Date
JP2013545759A true JP2013545759A (ja) 2013-12-26
JP2013545759A5 JP2013545759A5 (enExample) 2015-01-15

Family

ID=45217701

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013540063A Pending JP2013545759A (ja) 2010-11-18 2011-11-18 低酸素状態に基づくエレスクロモールによる治療に適した被験体の事前選択

Country Status (4)

Country Link
US (2) US20120128580A1 (enExample)
EP (1) EP2640372A1 (enExample)
JP (1) JP2013545759A (enExample)
WO (1) WO2012068491A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021162478A1 (ko) * 2020-02-14 2021-08-19 사회복지법인 삼성생명공익재단 게니핀 및 엘레스클로몰을 포함하는 암 예방 또는 치료용 약학적 조성물
WO2023276768A1 (ja) * 2021-06-29 2023-01-05 国立大学法人京都大学 低酸素バイオマーカー及びその利用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130149392A1 (en) * 2011-12-12 2013-06-13 Synta Pharmaceuticals Corp. Method of treating non-small cell lung cancer with bis-(thiohydrazide)amide compounds
EP3880189A4 (en) * 2018-11-14 2022-08-03 The Broad Institute, Inc. USE OF DISULFIRAM AND OTHER COMPOUNDS TO TREAT CANCER WITH CHROMOSOME 16Q LOSS AND/OR LOW EXPRESSION OF METALLOTHIONEINPROTEINS
CN112618527B (zh) * 2021-01-20 2021-11-09 上海交通大学医学院附属第九人民医院 一种小分子在制备突变型葡萄膜黑色素瘤药物中的应用
CA3235940A1 (en) * 2021-10-21 2023-04-27 Jeffrey A. BACHA Compositions and methods for treatment of hyperproliferative, inflammatory, and immunological diseases, and infections
CN115581775B (zh) * 2022-09-26 2025-09-30 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） 一种用于治疗骨肉瘤的复合纳米药剂及其制备方法
CN118453879B (zh) * 2024-05-23 2025-10-03 大连医科大学附属第二医院 恩杂鲁胺与铜离子载体联合在制备前列腺癌治疗药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009079338A1 (en) * 2007-12-14 2009-06-25 Sciclone Pharmaceuticals, Inc. Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (hsaa)
WO2011133673A1 (en) * 2010-04-20 2011-10-27 Synta Pharmaceuticals Corp. Use of bis [thiohydrazide amide] compounds such as elesclomol for treating cancers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4250255A (en) 1977-07-11 1981-02-10 Eastman Kodak Company Assay method for isoenzyme activity
US6242208B1 (en) 1988-07-15 2001-06-05 International Reagents Corporation LDH1 assay
KR101313027B1 (ko) 2004-06-23 2013-10-02 신타 파마슈티칼스 코프. 암 치료용 비스(티오-히드라지드 아미드) 염
EP1731617A1 (de) 2005-06-06 2006-12-13 DSM IP Assets B.V. Rückführung lysierter Biomasse als Nährmedium bei der fermentativen Herstellung von Riboflavin
SE530596C2 (sv) 2006-10-13 2008-07-15 Mathias Karlsson Metod att fastställa syrebrist i blod från skalpen under förlossning
WO2008103202A2 (en) 2006-11-21 2008-08-28 Beth Israel Deaconess Medical Center Hypoxia related genes and proteins for the treatment and diagnosis of pregnancy related complications

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009079338A1 (en) * 2007-12-14 2009-06-25 Sciclone Pharmaceuticals, Inc. Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (hsaa)
WO2011133673A1 (en) * 2010-04-20 2011-10-27 Synta Pharmaceuticals Corp. Use of bis [thiohydrazide amide] compounds such as elesclomol for treating cancers

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN5014001402; 'ＳＹＮＴＡ　ＰＨＡＲＭＡＣＥＵＴＩＣＡＬＳ　ＡＮＮＯＵＮＣＥＳ　ＵＰＤＡＴＥＤ　ＥＬＥＳＣＬＯＭＯＬ　ＳＹＭＭＥＴＲＹＳＭ　ＤＡＴＡ　ＰＲＥＳＥＮＴＥＤ　ＡＴ　ＭＥＬＡＮＯＭＡ　ＸＩＩＩ' ［ＯＮＬＩＮＥ］ , 20091014 *
JPN7015002660; Ｃａｎｃｅｒ　Ｒｅｓｅａｒｃｈ，　２０１０，　Ｖｏｌ．７０（８　Ｓｕｐｐｌｅｍｅｎｔ），　ｐ．４５４５ *
JPN7015002661; Ｓｙｎｔａ　Ｐｒｅｓｅｎｔｓ　Ｎｅｗ　Ｄａｔａ　ｏｎ　Ｅｌｅｓｃｌｏｍｏｌ　（Ｆｏｒｍｅｒｌｙ　ＳＴＡ-４７８３）　ａｔ　ＡＡＣＲ-ＮＣＩ-ＥＯＲＴＣ　Ｉｎｔｅｒｎａｔｉｏｎａｌ　Ｃｏｎｆｅｒｅｎｃｅ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021162478A1 (ko) * 2020-02-14 2021-08-19 사회복지법인 삼성생명공익재단 게니핀 및 엘레스클로몰을 포함하는 암 예방 또는 치료용 약학적 조성물
WO2023276768A1 (ja) * 2021-06-29 2023-01-05 国立大学法人京都大学 低酸素バイオマーカー及びその利用

Also Published As

Publication number Publication date
US20120128580A1 (en) 2012-05-24
US20140113972A1 (en) 2014-04-24
WO2012068491A1 (en) 2012-05-24
EP2640372A1 (en) 2013-09-25

Similar Documents

Publication Publication Date Title
US20140178366A1 (en) Preselection of subjects for therapeutic treatment based on hypoxic status
Levy et al. Targeting autophagy in cancer
Pallet et al. High prevalence of and potential mechanisms for chronic kidney disease in patients with acute intermittent porphyria
US20140113972A1 (en) Preselection of subjects for therapeutic treatment with elesclomol based on hypoxic status
US20140024030A1 (en) Preselection of subjects for therapeutic treatment with oxygen sensitive agents based in hypoxic status
Majumder et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways
US20150253330A1 (en) Pre-selection of subjects for therapeutic treatment with an hsp90 inhibitor based on hypoxic status
Kebebew et al. A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer
JP7399135B2 (ja) がんにおけるマクロピノサイトーシス
WO2012178038A1 (en) Methods of treating cancer
JP2022500479A (ja) Ｃｄｃ７阻害剤を含む癌の治療方法
KR101242726B1 (ko) 종양줄기세포 특성 암의 진단 및 치료제
Wasko et al. Tumor-selective effects of active RAS inhibition in pancreatic ductal adenocarcinoma
CN101512343A (zh) 黑素瘤抑制性活性蛋白（mia）作为在黑素瘤治疗性反应中的早期指示物的应用
EP2453234B1 (en) Methods for prognosing the ability of a zearalenone analog compound to treat cancer
EP4103286A1 (en) Method of treating pancreatic cancer
Sung et al. Ischemia‐induced cardiac dysfunction is exacerbated in adiponectin‐knockout mice due to impaired autophagy flux
Peng et al. Identification of Bruceine A as a novel HSP90AB1 inhibitor for suppressing hepatocellular carcinoma growth
EP2407786A1 (en) Method for predicting therapeutic efficacy of chemotherapy on non-small-cell lung cancer
CN116492471A (zh) 一种治疗braf v600e突变晚期结直肠癌的组合药物
EP2610620A1 (en) Histone deacetylase 10-inhibitor co-treatment in cancer
Tang et al. PRC1 mediates downstream PI3K-AKT activation through regulating PTEN ubiquitination degradation in TAC-induced cardiac remodeling
Xi et al. Targeting the MDK/c‐Myc complex to overcome temozolomide resistance in glioma
WO2021078937A1 (en) Treatment of stat3 related diseases by iron chelators
CN111434353A (zh) Ras抑制剂筛选及疗效标志物

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20140224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141118

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150929

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151221

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160712